Arcutis Biotherapeutics, Inc. ARQT
28.38 USD +0.99 (+3.63%)
At closeNov 11, 2026, 4:00 PM EST
28.38 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
27.20 Day range 28.65
19.30 52-week range 34.80
- YTD
- -2.27%
- 1 year
- +18.10%
News
defenseworld.net Arcutis Biotherapeutics (NASDAQ:ARQT) EVP Sells $1,372,800.00 in Stock Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) EVP Masaru Matsuda sold 40,000 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an…- defenseworld.net Arcutis Biotherapeutics (NASDAQ:ARQT) EVP Sells $1,372,800.00 in Stock Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) EVP Masaru Matsuda sold 40,000 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an…
globenewswire.com Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in…
benzinga.com TD Cowen Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40 TD Cowen analyst Tyler Van Buren maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $40.
benzinga.com Zillow Posts Downbeat Q3 Results, Joins HubSpot, Snap And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures were mixed as Zillow and several companies fell sharply premarket after weak results and lowered sales guidance.- benzinga.com Arcutis Biotherapeutics Initiates Enrollment In Its INTEGUMENT-3 Trial To Evaluate ZORYVE To Treat Atopic Dermatitis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first…
globenewswire.com Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitis Study aims to expand once-daily…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers ADMA Biologics (NASDAQ:ADMA) shares rose 19.6% to $12.53 during Thursday's pre-market session. The market value of their outstanding shares is at $2.3 billion. As per the news, the Q3…
benzinga.com Why AppLovin Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket AppLovin surged 16.5% premarket after Q3 revenue and EPS beat estimates and Q4 guidance topped forecasts; MNTN plunged 42.3% on weak results.
benzinga.com Arcutis Biotherapeutics Announces $200M At-The-Market Common Stock Offering ARCUTIS BIOTHERAPEUTICS, INC.$200,000,000Common StockWe have entered into an amended and restated sales agreement, or the Sales Agreement, with TD Cowen, relating to shares of our common stock…
benzinga.com Arcutis Biotherapeutics Q3 2026 Earnings Call Transcript Arcutis Biotherapeutics (NASDAQ:ARQT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the…- benzinga.com Arcutis Biotherapeutics Q3 EPS $0.06 Misses $0.12 Estimate, Sales $143.919M Beat $142.592M Estimate Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.12 by 50 percent. This is unchanged from the same period last…
benzinga.com Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44 Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $38 to $44.
benzinga.com Why Is Arcutis Biotherapeutics Stock Surging Thursday? Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.- benzinga.com Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48 Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight rating and announces Price Target of $48.